SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David B. Higgs who wrote (112)2/24/1997 7:58:00 PM
From: Joe Williamson   of 371
 
Paul Herron said he believes Leukoscan will not receive the expedited approval they requested but commented that FDA reviews have been completed more quickly in the past year. Since the technology is similar to CEA-Scan approval should come more quickly. As far as a marketing partner for Leukoscan he couldn't say when one would be announced. He suggested that nothing was "imminent" but that I shouldn't get the impression that it would take several months either. He also doesn't know when Lehman would begin coverage; it's dependent upon Lehman's time schedule. Finally I asked him why he hadn't bought shares (he sold some options when the stock went to 12 last summer). He said he in fact had bought some shares recently; they do not show up as insider buys because he is not an insider.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News